S*BIO Pte signs two-year R&D accord with IMCB

19 February 2007

Singapore-based biotechnology company S*BIO Pte, a specialist in the development of small-molecule drugs for the treatment of cancer, says it has signed a two-year Master Research Collaboration Agreement with the country's Institute of Molecular Cell Biology (IMCB), which is part of the Agency for Science, Technology and Research (A*STAR). The company said that the research would focus on the development of multiple compounds for the treatment of cancers, and added that it would develop any promising candidates to the clinical assessment stage, in partnership with A*STAR's newly-formed Experimental Therapeutics Center. Further financial details of the collaboration agreement were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight